Ligand id: 6884

Name: eculizumab

No information available.
Summary of Clinical Use
Used to treat paroxysmal nocturnal hemoglobinuria. In the UK, NICE (National Institute for Health and Care Excellence) has approved eculizumab as a treatment for the rare, but fatal blood disorder, atypical haemolytic uraemic syndrome (aHUS). This descision was reached because eculizumab represents a significant innovation for a disease with a high unmet clinical need. Eculizumab treatment is expected to increase life expectancy of aHUS patients by decades.
Mechanism Of Action and Pharmacodynamic Effects
This antibody blocks the cleavage of the complement protein C5 and thereby prevents the formation of C5a and the membrane attack complex, which lowers the risk of blood clot formation and intravascular hemolysis, the most common thrombotic complications underlying mortality in PNH patients.